Adaptimmune Inc. (NASDAQ: ADAP) stock declines by 1.60% in the current market trading session. Adaptimmune is a clinical-stage biotech firm focusing on developing new cancer immunotherapy medicines for cancer patients.
ADAP stock’ Significant Development
Updated data from Adaptimmune Therapeutics Phase 1 SURPASS trial in multiple solid tumors has been released. The data will be discussed in a digital poster at the annual meeting of the European Society for Medical Oncology (ESMO). On Thursday, September 16th, the poster will be posted on the ESMO convention website. The highlights of the data are as follows:
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
- Ovarian cancer had a proven complete response, and ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma tumors had confirmed half responses.
- Most of patients witnessed antitumor activity, with an 86 percent disease control rate.
- ADP-A2M4CD8 cell therapy improves tumor cell killing and immune system engagement in the fight against cancer.
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
Adrian Rawcliffe, Adaptimmune’s CEO stated,
Their SPEAR T-cells are unquestionably effective against a variety of MAGE-A4-expressing tumors. Their priority now is to transform them into FDA-approved treatments. This starts with the continuing SURPASS trial for persons with lung, bladder, gastroesophageal, head and neck, and now ovarian cancer, and continues with the newly launched SURPASS 2 trial for esophageal and EGJ malignancies. These findings help them narrow down which additional indications they should pursue in late-stage development and also confirm their competence and efficacy in developing and improving cell therapies.
Dr. David Hong, Professor, Deputy Chairman in the Department of Investigational Cancer Therapeutics (Phase I Program) at The University of Texas MD Anderson Cancer Center mentioned that They are delighted by these encouraging early data from the SURPASS trial. After seeing positive results with afami-cel, this next-generation cell therapy appears to be safe and has proven anticancer effectiveness in a large number of patients with a variety of cancers.